Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to observe ancient rituals by indulging in fattening customs, catch up on our reading, and promenade with the official mascot. And what about you? As the year-end holidays get under way, you could boost the economy by purchasing a few gifts. You could double-check to see if the election has been decided. Or touch base with someone feeling isolated these days. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

Sanofi (SNY) suffered a major setback in producing a Covid-19 vaccine, STAT reports. The problem will push the timeline for deployment — if the vaccine is approved — from the first half of 2021 into the second half of the year. The news is also disappointing for multiple countries, including the U.S., as well as the European Union, that have purchase contracts. Sanofi had hoped to start a Phase 3 trial this month and projected it could produce 100 million doses of vaccine in 2020, and 1 billion doses in 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.